Skip to main content

Table 3 The pooled results and evidence quality in safety outcomes

From: Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies

Outcome

RCT

NRCT

Cohort study

Estimate (95% CI)

Evidence quality a

Estimate (95% CI)

Evidence quality a

Estimate (95% CI)

Evidence quality a

Myelosuppression

RR 0.55 (0.32–0.96) *

Moderate

RR 0.38 (0.20–0.72) *

Low

RR 1.11 (0.59–2.10)

Very low

 Grade 3/4 myelosuppression

RR 0.70 (0.29–1.66)

Low

RR 0.20 (0.01–3.92)

Very low

RR 1.25 (0.30–5.15)

Very low

 Leukopenia

–

–

RR 0.44 (0.18–1.11)

Very low

RR 1.12 (0.79–1.58)

Very low

 Grade 3/4 leukopenia

–

–

–

–

RR 0.80 (0.33–1.93)

Very low

 Neutropenia

–

–

RR 0.55 (0.28–1.06)

Very low

RR 1.04 (0.89–1.22)

Very low

 Grade 3/4 neutropenia

–

–

–

–

RR 0.96 (0.64–1.43)

Very low

 Anemia

–

–

RR 0.43 (0.14–1.33)

Very low

RR 1.05 (0.92–1.20)

Very low

 Grade 3/4 anemia

–

–

–

–

RR 0.95 (0.46–1.97)

Very low

 Thrombocytopenia

–

–

–

–

RR 1.15 (0.74–1.79)

Very low

 Grade 3/4 thrombocytopenia

–

–

–

–

RR 1.30 (0.49–3.47)

Very low

 Hemorrhage

–

–

–

–

–

–

 Grade 3/4 hemorrhage

–

–

–

–

–

–

 Laryngeal hemorrhage

–

–

–

–

RR 0.27 (0.09–0.84) *

Very Low

Cardiovascular toxicity

RR 0.21 (0.06–0.78) *

Moderate

RR 0.15 (0.02–1.20)

Very low

–

–

 Cardiotoxicity

–

–

RR 0.26 (0.06–1.13)

Very low

–

–

Gastrointestinal Reaction

–

–

RR 0.83 (0.30–2.29)

Very low

RR 1.25 (0.30–5.15)

Very low

 Grade 3/4 gastrointestinal response

–

–

RR 0.67 (0.12–3.57)

Very low

–

–

 Nausea & vomiting

RR 0.88 (0.51–1.51)

Low

RR 0.58 (0.25–1.36)

Very low

RR 0.97 (0.72–1.31)

Very low

 Grade 3/4 nausea & vomiting

RR 1.00 (0.38–2.60)

Low

RR 1.00 (0.16–6.14)

Very low

RR 1.25 (0.35–4.42)

Very low

 Nausea

–

 

–

–

RR 1.17 (0.32–4.28)

Very low

 Vomiting

–

 

–

–

RR 1.23 (0.63–2.40)

Very low

 Diarrhea

RR 1.43 (0.60–3.40)

Low

–

–

RR 0.60 (0.18–1.96)

Very low

 Constipation

–

 

–

–

RR 0.90 (0.53–1.54)

Very low

Alopecia

RR 0.95 (0.82–1.09)

Moderate

RR 0.65 (0.42–1.00) *

Very low

RR 0.78 (0.31–1.95)

Very low

Neurotoxicity

RR 0.80 (0.23–2.77)

Low

–

–

–

–

 Peripheral neurotoxicity

–

 

–

–

RR 0.58 (0.14–2.33)

Very low

Liver dysfunction

RR 0.71 (0.39–1.29)

Low

–

–

RR 0.63 (0.20–2.01)

Very low

 Grade 3/4 liver dysfunction

RR 0.60 (0.15–2.35)

Low

–

–

–

 

 Transaminase elevation

–

 

–

–

RR 1.48 (0.84–2.62)

Very low

Fatigue

RR 1.14 (0.87–1.50)

Moderate

–

–

RR 0.90 (0.64–1.27)

Very low

 Grade 3/4fatigue

RR 1.17 (0.43–3.18)

Low

–

–

–

–

Muscle & joint soreness

RR 0.71 (0.30–1.71)

Low

–

–

–

–

Rash

–

–

–

–

RR 0.61 (0.10–3.73)

Very low

 Papule and purulent herpes

–

–

–

–

RR 1.60 (0.49–5.25)

Very low

Fever

–

–

–

–

RR 0.95 (0.48–1.88)

Very low

Thromboembolism

–

–

–

–

RR 0.48 (0.07–3.19)

Very low

Hyponatremia

–

–

–

–

RR 1.28 (0.71–2.29)

Very low

 Grade 3/4 hyponatremia

–

–

–

–

RR 0.48 (0.10–2.19)

Very low

Pain

–

–

–

–

RR 1.00 (0.37–2.67)

Very low

  1. a The evidence quality was evaluated by GRADE. Moderate: we are moderately confident in the effect estimate (the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different); Low: our confidence in the effect estimate is limited (the true effect may be substantially different from the estimate of the effect); Very low: we have very little confidence in the effect estimate (the true effect is likely to be substantially different from the estimate of effect)
  2. * A statistically significant difference exists (P < 0.05)